Related Experiment Video
Updated: Jan 18, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Botulinum Toxin Injection in Retrograde Cricopharyngeal Dysfunction: A Meta-Analysis
Wei Xin Yeo1, Benjamin Kye Jyn Tan1,2, Esther Yanxin Gao1
1Department of Otorhinolaryngology-Head & Neck Surgery, Singapore General Hospital, Singapore, Singapore.
Objective:
Retrograde cricopharyngeal dysfunction (RCPD) is defined by the inability to burp, sometimes with gurgling, chest/abdominal discomfort, and excessive flatulence. Treatment involves cricopharyngeal Botulinum Toxin-A (BonT-A) injection. However, the optimal dose and route are unclear. We quantitatively summarize the efficacy, safety, and optimization of BonT-A injections for RCPD.
Data Sources:
PubMed, Embase, Scopus; till October 19, 2024.
Review Methods:
We included randomized and non-randomized studies, published as full-length peer-reviewed articles, that investigated the efficacy and safety of BonT-A injections for RCPD among participants of all ages. Two blinded authors selected studies, extracted data, and evaluated bias (ROBINS-I), following a PROSPERO-registered protocol (CRD42024606413). We pooled logit-transformed proportions using random-effects inverse-variance meta-analyses, identified associated factors using meta-regression, and quantitatively analyzed publication bias.
Results:
From 189 records, we included 13 single-arm case series (N = 699), with some concerns for bias. Pooled early (1-4 weeks) and sustained (mean 3-29 months) overall symptom relief were 91.45% (95% CI = 83.66%-95.72%, I 2 = 72%) and 79.90% (95% CI = 70.76%-86.72%, I 2 = 53%) respectively. Complications were minor; the most common was transient dysphagia (51.04%, 95% CI = 37.61%-64.32%, I 2 = 71%). Injections under direct rigid-endoscopic visualization were associated with greater (p = 0.0096) early success (92.19%, 95% CI = 88.29%-94.86%, I 2 = 18%) than percutaneous electromyography-guided injections (85.03%, 95% CI = 21.90%-99.14%, I 2 = 78%). Higher BonT-A dose (from 50 to 100 units) was associated with higher (p = 0.0382) sustained success (71.36%-92.79%); diminishing returns were projected for subsequent increments. Publication bias was not evident.
Conclusions:
Cricopharyngeal BonT-A injections are safe and efficacious in RCPD. Larger doses of 100 units, injected under direct rigid-endoscopic visualization, may improve and maintain success. Randomized studies are needed to confirm causality.
More Related Videos
06:30Assessment of Static Graviceptive Perception in the Roll-Plane using the Subjective Visual Vertical Paradigm
Published on: April 28, 2020
05:50Subcutaneous Neurotrophin 4 Infusion Using Osmotic Pumps or Direct Muscular Injection Enhances Aging Rat Laryngeal Muscles
Published on: June 13, 2017
Related Concept Videos
Skeletal Muscle Relaxants: Therapeutic Uses
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Depolarizing Blockers: Pharmocokinetics
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses